On a spree, Allergan forks over a big premium to nab Vitae’s autoimmune drugs for $639M
Allergan’s buyout spree continued today, this time with a deal to bag Vitae Pharmaceuticals $VTAE for $21 a share, or $639 million in cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
